Privately-held drug developer LIB Therapeutics has claimed FDA approval for a new once-monthly PCSK9 inhibitor – Lerochol – that can be used to reduce cholesterol levels. The injectable product has ...
LIB Therapeutics Inc. (LIB), a privately-held, biopharmaceutical company with a recently approved novel, monthly, small dose third-generation PCSK9 inhibitor, LEROCHOL ® (lerodalcibep-liga), today ...
The popular local family-run restaurant Liberatore’s and its more casual Lib’s Grill spinoff are opening more locations. John Liberatore announced that his namesake restaurant will “finally” be coming ...
LIB Therapeutics has passed another milestone on its path to launching a challenger to cholesterol drugs sold by Amgen, Regeneron and Sanofi. In the latest phase 3 readout, the private biotech’s ...
CINCINNATI & SHANGHAI--(BUSINESS WIRE)--LIB Therapeutics Inc. (“LIB”) and Hasten Biopharmaceutical Co., Ltd. (“Hasten”), today announce that the companies have entered into an agreement granting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results